NAMSW
NewAmsterdam Pharma Company N.V.
NASDAQ · Healthcare · Biotechnology · NL
$13.88
−3.88%Year over year
Reported trailing growth
- Revenue
- -88.9%
- EBITDA
- -32.5%
- EBIT
- -41.4%
- EPS
- -32.1%
- Free cash flow
- -15.6%
- Operating cash flow
- -15.6%
Forward estimates
Based on analyst estimates
- Revenue
- +285.1%
- EBITDA
- -4.1%
- EPS
- +1.2%
Three-year CAGR
- Revenue
- -39.7%
- EBITDA
- -0.3%
- EBIT
- -28.0%
- Net income
- +15.6%
- EPS
- +31.6%
- Free cash flow
- +7.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026